TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02893072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized medical nutrition therapy
Description: The intervention group involves dietary and exercise advice and monitoring.
Study: NCT04612647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week FMS Intervention
Description: 4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activities & Activity Booklets
Description: expected to engage in physical activity at least 3 hours per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activities & Activity Booklets
Description: expected to engage in physical activity at least 3 hours per week
Study: NCT02293226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoopDech
Description: Video-laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoopDech
Description: Video-laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: video-laryngoscopy 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: video-laryngoscopy 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-laryngoscopy 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-laryngoscopy 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vividtrack
Description: video-laryngoscopy 4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vividtrack
Description: video-laryngoscopy 4
Study: NCT05782751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GROUPI
Description: 10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
Study: NCT05782751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GROUP II
Description: 10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
Study: NCT04176900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ingeo Biopolymer (PLA)
Description: Biopolymer used for 3D-printing of rigid bolus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecoflex 030
Description: Polymer used for the 3D-printed flexible bolus
Study: NCT03346499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells and IL-2
Description: Natural Killer Cells
Study: NCT02050282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplementary NT-proBNP measurement
Description: In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
Study: NCT02636023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPhENo-Cardiograph
Description: SPhENo-Cardiograph
Study: NCT03895255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization
Description: Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization
Description: Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
Study: NCT02916251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207(dasiglucagon) glucagon analogue
Description: Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (Native glucagon)
Description: Cross-over design with single s.c. administration in euglycemic T1D
Study: NCT03090555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Translational manipulation
Description: After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
Study: NCT00952887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031
Description: Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
Study: NCT03419065

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Intervention
Description: Relaxing Music combined with Progressive Muscle relaxation and guided imagery
Study: NCT04787055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument
Description: Receiver-in-canal hearing instrument

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument
Description: Receiver-in-canal hearing instrument
Study: NCT02349685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: H. pylori culture and antimicrobial susceptibility test
Description: Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
Study: NCT00564447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin topical solution given as a single drop in a single eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin topical solution given as a single drop in a single eye
Study: NCT02349685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 day PBMT group
Description: Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 day MEA group
Description: Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
Study: NCT02906267

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic ultrasonography of gastric volume
Description: Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic ultrasonography of gastric volume
Description: Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic ultrasonography of gastric volume
Description: Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
Study: NCT01816867

Intervention type: DEVICE
Intervention: Intramesh T1 implantation
Study: NCT04073485

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microwave ablation
Description: Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
Study: NCT03981068

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Cisplatin for all eligible patients, nimorazole for all SCC
Study: NCT01162811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visualization together with structured behavioural attention.
Description: visualization and relaxation exercises together with structured behavioural attention.
Study: NCT00708695

Intervention type: BEHAVIORAL
Intervention: Nurse Home Visiting
Description: Visits from nurses from mid-pregnancy to child age 2 years.
Study: NCT02807870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental training
Description: Weekly parental training conducted by behavioral psychologists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational groups for parents
Description: Weekly psychoeducational groups conducted by educators.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational groups for parents
Description: Weekly psychoeducational groups conducted by educators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill during 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill during 8 weeks.
Study: NCT00959127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-438162 (MEK162), MEK inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study: NCT00151372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Adherence Intervention
Description: The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
Study: NCT00960479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
Study: NCT01912339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum System
Description: The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rigid Cystoscopy
Description: Endoscopy of the urinary bladder via the urethra.
Study: NCT01773304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary meal intervention
Description: Test meals with different protein types (dairy versus meat)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary meal intervention
Description: Test meals with different protein types (dairy versus meat)
Study: NCT00528801

Intervention type: BEHAVIORAL
Intervention: NP Battery
Description: Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.

Intervention type: BEHAVIORAL
Intervention: NP Battery
Description: Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.

Intervention type: PROCEDURE
Intervention: MRI
Description: The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.

Intervention type: PROCEDURE
Intervention: MRI
Description: The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
Study: NCT03721497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone Undecanoate
Description: The patients will be randomly assigned to either testosterone or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: The patients will be randomly assigned to either testosterone or placebo.
Study: NCT00679172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 5.0 x 10^9 CFU (Cohort 1)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 7.5 x 10^9 CFU (Cohort 2)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 1.1 x 10^10 CFU (Cohort 3)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of of 1.7 x 10^10 CFU (Cohort 4)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Cohorts 1-4 pooled)
Description: Excipients only, single dose, oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Cohorts 1-4 pooled)
Description: Excipients only, single dose, oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Cohorts 1-4 pooled)
Description: Excipients only, single dose, oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Cohorts 1-4 pooled)
Description: Excipients only, single dose, oral administration
Study: NCT01910467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS visible and predefined interventions
Description: NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS not visible and treatment as usual
Description: NIRS not visible and the patients will be treated according to routine
Study: NCT04359979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: selective alpha1 receptor antagonist
Study: NCT01058629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynergEyes A2 Hybrid Contact Lens
Description: SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
Study: NCT03720288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
Study: NCT04438291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDL-SHPVP
Description: A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games

Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute educational video
Description: A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
Study: NCT02408523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide Tablet
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT03907488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study: NCT02497911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Study: NCT04306211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SuperNO2VA
Description: SUPERNO2VA is nasal PAP device for oxygen delivery
Study: NCT03161665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMT Roadmap
Description: The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.